The financials
Agilent Technologies by the numbers
Agilent Technologies (A) reported revenue of $1.88B in Q3 2026 (quarter ended Jul 31, 2026), up 8.1% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $362M (19% of revenue). For the full year FY2025, revenue was $6.95B (+6.7% year on year) and net income $1.30B. Its largest segment in Q2 2026 (quarter ended Apr 30, 2026) was Life Sciences And Diagnostics Markets at $363M, 48% of the disclosed total, ahead of Agilent Cross Lab at 38%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.88B | $1.74B | +8.1% |
| Gross profit | $1.04B | $888M | +17% |
| Operating income | $444M | $360M | +23% |
| Net income | $362M | $336M | +7.7% |
| Diluted EPS | $1.28 | $1.18 | +8.5% |
| Operating | Revenue | Share |
|---|---|---|
| Life Sciences And Diagnostics Markets | $363M | 48% |
| Agilent Cross Lab | $289M | 38% |
| Applied Markets | $112M | 15% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $764.0M (+13%)
Applied Markets grew +35% year on yearAgilent Cross Lab +7.0% year on year
Segment Latestquarter on quarteryear on year
- Life Sciences And Diagnostics Markets$363.0M$363.0MQoQ +18%year on year +12%+18%+12%
- Agilent Cross Lab$289.0M$289.0MQoQ +5.9%year on year +7.0%+5.9%+7.0%
- Applied Markets$112.0M$112.0MQoQ +14%year on year +35%+14%+35%
Diagnostics & Research
The closest names by size in the same industry